SPL
Massive earnings potential for Vivagel.
At least 100m USD/annum , very conservatively, more likely double that.
Only drug in a billion USD market.
This gives 7 bucks per share based upon Vivagel alone.
The DEP platform is the main game;
DEP docetaxel trial almost finished. Chemo drug without hair loss or neutropenia.
Multi billion dollar market.
Astrazenica has licensed a couple of candidates. 100s of millions in milestone payments and 15 percent royalties for each drug.
Many other strings to their bow.
Sounds retarded, but could see a 50 dollar SP in the future.
Should be a good day trade. Over 6m outstanding shorts. Make em piss...
Cheers
- Forums
- ASX - Day Trading
- DT Pre Market Jan 13 2017
DT Pre Market Jan 13 2017, page-16
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)